Navigation Links
Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety
Date:9/27/2011

ccines, in combination with Inovio's proprietary CELLECTRA® delivery method, have been shown in humans to be safe and generate best-in-class immune responses. Inovio's clinical programs include Phase II studies for cervical dysplasia/cancer, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
2. Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
3. Inovio Pharmaceuticals to Present at Investor Conferences
4. Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results
5. Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I
6. Inovio Pharmaceuticals Announces Transition of Avtar Dhillon to Non-Executive Chairman of the Board
7. Inovio Pharmaceuticals to Present at Scientific & Industry Conferences
8. Inovio Pharmaceuticals Subsidiary, VGX Animal Health, to Present at VetHealth Global 2011, June 14-17, 2011
9. Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011
10. Inovio Pharmaceuticals Market-Leading Intellectual Property Recognized by MDB Capital Award
11. Inovio Pharmaceuticals to Present at Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Actavis plc (NYSE: ACT ... a complete response letter from the U.S. Food ... Application (NDA) for the fixed-dose combination (FDC) of ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... receipt of a complete response letter, Actavis remains ...
(Date:12/24/2014)... 24, 2014 Kinex Pharmaceuticals announced today that ... Roswell Park Cancer Institute. KX2-361 (KX02), a ... has shown potent inhibitory activity against a broad panel ... resistant to Temozolomide (T98G), the most widely used chemotherapy ... brain tumor mouse model, KX2-361 consistently clears brain tumors ...
(Date:12/24/2014)... , Dec. 24, 2014  Conkwest, Inc., the ... the proprietary Natural Killer (NK) cell-line platform, Neukoplast® ... Patrick Soon-Shiong , NantWorks founder, physician scientist ... agreement to purchase approximately $48 million of the ... the investment, he will be named Co-Chairman of ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5
... 2, 2011 Omnicell, Inc. (NASDAQ: OMCL ), a ... today announced results for its first quarter ended March 31, 2011. ... quarter of 2011 was $57.2 million as compared with $57.3 ... million or 5.5% from the first quarter 2010 revenue of ...
... (Hologic or the Company) (Nasdaq: HOLX ), a ... imaging systems and surgical products dedicated to serving the healthcare ... fiscal quarter ended March 26, 2011. ... $438.7 million. Net income was $82.4 million, or $0.31 ...
Cached Medicine Technology:Omnicell Announces First Quarter 2011 Results 2Omnicell Announces First Quarter 2011 Results 3Omnicell Announces First Quarter 2011 Results 4Omnicell Announces First Quarter 2011 Results 5Omnicell Announces First Quarter 2011 Results 6Omnicell Announces First Quarter 2011 Results 7Omnicell Announces First Quarter 2011 Results 8Omnicell Announces First Quarter 2011 Results 9Omnicell Announces First Quarter 2011 Results 10Hologic Announces Second Quarter Fiscal 2011 Operating Results 2Hologic Announces Second Quarter Fiscal 2011 Operating Results 3Hologic Announces Second Quarter Fiscal 2011 Operating Results 4Hologic Announces Second Quarter Fiscal 2011 Operating Results 5Hologic Announces Second Quarter Fiscal 2011 Operating Results 6Hologic Announces Second Quarter Fiscal 2011 Operating Results 7Hologic Announces Second Quarter Fiscal 2011 Operating Results 8Hologic Announces Second Quarter Fiscal 2011 Operating Results 9Hologic Announces Second Quarter Fiscal 2011 Operating Results 10Hologic Announces Second Quarter Fiscal 2011 Operating Results 11Hologic Announces Second Quarter Fiscal 2011 Operating Results 12Hologic Announces Second Quarter Fiscal 2011 Operating Results 13Hologic Announces Second Quarter Fiscal 2011 Operating Results 14Hologic Announces Second Quarter Fiscal 2011 Operating Results 15Hologic Announces Second Quarter Fiscal 2011 Operating Results 16Hologic Announces Second Quarter Fiscal 2011 Operating Results 17Hologic Announces Second Quarter Fiscal 2011 Operating Results 18
(Date:12/25/2014)... Dec. 25, 2014 (HealthDay News) -- Overeating is common during ... eat in moderation, an expert says. "Don,t arrive at ... calories if you know you,ll be attending a party, but ... Ashbey-Pejoves, lead dietitian at Northern Westchester Hospital in Mount Kisco, ... to eat healthy during the day and even to have ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the ... the business has introduced its new collection of 2015 ... , The new prom outfits are guaranteed to contain ... They are specially designed for 2015. Anyone who wants ... visit its website before Jan. 26, 2015, the deadline ...
(Date:12/25/2014)... Aliso Viejo, California (PRWEB) December 25, 2014 ... the release of ProFire 5k. A fully customizable business ... X . , “Adding the ProFire 5k business tool, ... style” Said Christina Austin, CEO of Pixel Film Studios. ... the look and style to add professionalism to a ...
(Date:12/25/2014)... 25, 2014 Parker & Sons, Inc. ... service and affordable quality regarding heating, cooling and plumbing ... in 2014 by the “Queen of Clean” for impressive ... an impressive reputation over the years for providing outstanding ... range of contractor services for both homeowners and businesses. ...
(Date:12/24/2014)... Epigenetics finds applications in a large number ... discovery, developmental biology, and research for metabolic and genetic ... most widely used techniques for the discovery and development ... cancer is rapidly growing worldwide. In 2012, there were ... and 32.6 million people living with cancer (within five ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3
... disorders may be linked to other medical problems including ... and psychiatric problems. ,Researchers conducted a study and ... had ADD. Results also show a high degree of ... of these patients also suffered severe memory impairment, depression, ...
... that giving adolescent girls estrogen treatments to keep them from ... on in life . Estrogen is thought to limit height ... women who had been assessed for estrogen therapy as girls ... had actually been treated with estrogen, and the other half ...
... 60 are affected by Parkinson’s disease. The condition is characterized ... from loss of facial rigidity // and a shuffling walk. ... of Parkinson’s disease may also be able to stop its ... found to completely halt the neurotoxic effects of a chemical ...
... study finds growth patterns in childhood can help predict which ... link a high birth weight, reaching peak growth at an ... having a low body mass index (BMI) at age 14, ... likelihood of the disease. ,For the study researchers used ...
... researchers suggest that the risk factors for heart attacks may ... studied, about two-thirds had at least one risk factor for ... of risk factors known as metabolic syndrome. One in three ... has been identified as a risk for heart disease and ...
... the number one cause of cancer death worldwide, accounting for ... disease is hard to detect in early and treatable stages, ... Studies have shown CT scans can identify the disease in ... lung cancer, but they also identify many noncancerous lesions in ...
Cached Medicine News:
Smaller than the kuglen hook, this manipulator offers excellent grasping or lifting of the nucleus. Blunt finger-like 0.5 mm two-prong tip. Round knurled handle with dull finish. Straight....
3 mm forked angled blades. Blade spread 7 mm. Flat serrated handle with polished finish. Overall length: 4.8 inches....
Nucleus divider with 1.25 mm tip and blade offset at a 60 degree angle is ideal for performing the "Phaco Chop" technique. Round knurled handle. Manufactured in titanium....
Flat 7 mm wide hook. Flat serrated handle with polished finish. Overall length: 5.1 inches....
Medicine Products: